Trial Profile
Safety study on PCI 32765 in combination with bortezomib in patients with mantle cell lymphoma.
Status:
Not stated
Phase of Trial:
Phase I
Latest Information Update: 19 Nov 2013
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Pharmacyclics
- 19 Nov 2013 Status changed from planning to unconfirmed.
- 07 Feb 2011 New trial record